Innovation

Vilnius enzyme designer Biomatter raises $18m Series A led by Astanor to build a lab and grow in the US

Lithuanian AI enzyme designer Biomatter has raised an $18m Series A led by Astanor to open a 2,000 m² Vilnius facility in 2027, expand its sales team and grow in the US.

Author
Sandra J. Barbara
Published
Reading time
1 min read
Views
Loading views
Vilnius enzyme designer Biomatter raises $18m Series A led by Astanor to build a lab and grow in the US

Lithuanian AI enzyme designer Biomatter has raised an $18m Series A led by Astanor to open a 2,000 m² Vilnius facility in 2027, expand its sales team and grow in the US.

Biomatter (biomatter.ai) is a Vilnius-based protein design company founded in 2018 (formerly Biomatter Designs). Its Intelligent Architecture platform combines generative AI with physics-based modelling to design enzymes starting from the target chemical reaction.

  • Series A: $18M (company figure), led by Astanor, Nov 2026. Funds a 2,000 m² Vilnius facility opening in 2027, a larger sales team and US growth.
  • Seed: €6.5M, Aug 2024, led by Inventure and UVC Partners.
  • Customers reported: AstraZeneca, BASF, Sanofi; worked with Thermo Fisher on SuperScript V reverse transcriptase.
  • Joined AstraZeneca BioVentureHub.
  • Founders: Laurynas Karpus (Co-founder & CEO), Vykintas Jauniškis (Co-founder), Irmantas Rokaitis (Co-founder).

What did you think of this story?

Written by

Sandra J. Barbara

60 stories on European Startup Insider

Have a story like this? Pitch it to us.

We publish founder profiles, company news and practical guides from across Europe.

You’ve finished this story

Up next

Helsinki's Stoa raises €3.5m pre-seed from Lifeline to take its construction-site AI to data centre builds

Stoa, which turns drawings, schedules and site reports into answers for construction crews, raised €3.5m led by Lifeline Ventures and will chase data centre projects in the Nordics, UK and US.